Comprehensive Genomic Profiling Market Report – Research, Industry Analysis Reports and Market Demands

Global Comprehensive Genomic Profiling Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Comprehensive Genomic Profiling Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Comprehensive Genomic Profiling by Company Revenue
- 3.2.2 Top 3 Comprehensive Genomic Profiling Players Market Share in 2025
- 3.2.3 Top 6 Comprehensive Genomic Profiling Players Market Share in 2025
3.3 Comprehensive Genomic Profiling Market: Overall Company Footprint Analysis
- 3.3.1 Comprehensive Genomic Profiling Market: Region Footprint
- 3.3.2 Comprehensive Genomic Profiling Market: Company Product Type Footprint
- 3.3.3 Comprehensive Genomic Profiling Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Comprehensive Genomic Profiling Consumption Value and Market Share by Type (2021-2026)
4.2 Global Comprehensive Genomic Profiling Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Comprehensive Genomic Profiling Consumption Value Market Share by Application (2021-2026)
5.2 Global Comprehensive Genomic Profiling Market Forecast by Application (2027-2032)

6 North America

6.1 North America Comprehensive Genomic Profiling Consumption Value by Type (2021-2032)
6.2 North America Comprehensive Genomic Profiling Market Size by Application (2021-2032)
6.3 North America Comprehensive Genomic Profiling Market Size by Country
- 6.3.1 North America Comprehensive Genomic Profiling Consumption Value by Country (2021-2032)
- 6.3.2 United States Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 6.3.3 Canada Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Comprehensive Genomic Profiling Consumption Value by Type (2021-2032)
7.2 Europe Comprehensive Genomic Profiling Consumption Value by Application (2021-2032)
7.3 Europe Comprehensive Genomic Profiling Market Size by Country
- 7.3.1 Europe Comprehensive Genomic Profiling Consumption Value by Country (2021-2032)
- 7.3.2 Germany Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 7.3.3 France Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 7.3.5 Russia Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 7.3.6 Italy Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Comprehensive Genomic Profiling Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Comprehensive Genomic Profiling Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Comprehensive Genomic Profiling Market Size by Region
- 8.3.1 Asia-Pacific Comprehensive Genomic Profiling Consumption Value by Region (2021-2032)
- 8.3.2 China Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 8.3.3 Japan Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 8.3.5 India Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 8.3.7 Australia Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)

9 South America

9.1 South America Comprehensive Genomic Profiling Consumption Value by Type (2021-2032)
9.2 South America Comprehensive Genomic Profiling Consumption Value by Application (2021-2032)
9.3 South America Comprehensive Genomic Profiling Market Size by Country
- 9.3.1 South America Comprehensive Genomic Profiling Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Comprehensive Genomic Profiling Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Comprehensive Genomic Profiling Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Comprehensive Genomic Profiling Market Size by Country
- 10.3.1 Middle East & Africa Comprehensive Genomic Profiling Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)
- 10.3.4 UAE Comprehensive Genomic Profiling Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Comprehensive Genomic Profiling Market Drivers
11.2 Comprehensive Genomic Profiling Market Restraints
11.3 Comprehensive Genomic Profiling Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Comprehensive Genomic Profiling Industry Chain
12.2 Comprehensive Genomic Profiling Upstream Analysis
12.3 Comprehensive Genomic Profiling Midstream Analysis
12.4 Comprehensive Genomic Profiling Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Comprehensive Genomic Profiling market size was valued at US$ 6462 million in 2025 and is forecast to a readjusted size of US$ 15343 million by 2032 with a CAGR of 13.1% during review period.
Comprehensive Genomic Profiling refers to clinical diagnostic and precision oncology solutions that use targeted next-generation sequencing, whole-exome sequencing, whole-transcriptome sequencing, or integrated DNA and RNA analysis to profile a broad range of cancer-related genes and molecular biomarkers. Major targets include single nucleotide variants, insertions and deletions, copy number alterations, gene fusions and rearrangements, as well as genomic signatures such as tumor mutational burden, microsatellite instability, and homologous recombination deficiency. Commercial offerings include centralized laboratory testing services, tissue and liquid biopsy assay kits, integrated testing systems, and associated bioinformatics solutions. These products are primarily used for targeted therapy selection, immunotherapy assessment, clinical trial matching, molecular classification, and resistance analysis. Key upstream inputs include specimen collection components, nucleic acid extraction and library preparation reagents, capture probes, amplification enzymes, sequencing flow cells, quality controls, reference standards, sequencing platforms, bioinformatics algorithms, and genomic databases. Major downstream customers include hospitals, cancer centers, independent clinical laboratories, pathology laboratories, pharmaceutical and biotechnology companies, and clinical research organizations. The estimated industry gross margin is generally approximately 50%–70%.
The global Comprehensive Genomic Profiling market is shifting rapidly from sequential single-gene testing toward integrated analysis of multiple genes and variant classes in a single assay. As the number of targeted therapies, immunotherapy biomarkers, and tumor-agnostic indications increases, sequential testing has become less efficient because of tissue consumption, longer turnaround times, and cumulative cost. Large genomic panels can evaluate multiple actionable alterations and complex genomic signatures in one test and are therefore gaining adoption among patients with advanced solid tumors, rare cancers, and limited standard treatment options. North America is dominated by centralized laboratory services, Europe and Japan rely more heavily on approved assay products and designated hospital networks, while China has developed a mixed structure combining third-party laboratories, hospital-based testing, and standardized domestic assay kits.
Tissue testing remains the foundation of Comprehensive Genomic Profiling, but liquid biopsy is becoming an important complementary option for patients with insufficient tissue, high biopsy risk, or a need for rapid results. Testing scope is expanding from targeted panels containing several hundred genes toward integrated DNA and RNA sequencing, matched tumor-normal analysis, whole-exome sequencing, and whole-transcriptome sequencing. RNA analysis improves the detection of gene fusions and abnormal splicing events, while matched-normal testing helps distinguish somatic alterations from germline variants and clonal hematopoiesis signals. Future competition will focus increasingly on performance in low-tumor-content specimens, fusion detection, turnaround time, clinical evidence, and the actionability of reported findings rather than on gene count alone.
Market growth is supported by the continued expansion of precision oncology, increasing numbers of tumor-agnostic targeted and immunotherapy indications, stronger clinical guideline recommendations, and broader availability of hospital NGS infrastructure. Drug development is gradually shifting from organ-of-origin classification toward molecular biomarker-driven patient selection. Pharmaceutical demand for companion diagnostics, patient screening, clinical trial matching, and real-world evidence provides testing companies with important revenue opportunities beyond routine patient testing. As sequencing costs decline, laboratory workflows become more automated, and reimbursement coverage improves in selected markets, Comprehensive Genomic Profiling is expected to expand from late-stage and rare cases toward earlier treatment stages and a broader patient population.
The industry nevertheless faces constraints related to specimen quality, testing costs, reimbursement, and the clinical conversion of genomic findings. Differences in gene coverage, sequencing depth, variant thresholds, and reporting rules may produce inconsistent results across laboratories. Some patients have potentially actionable alterations but cannot access matched treatment because of drug availability, regulatory indications, or the geographic location of relevant clinical trials. Competition between hospital-developed assays and centralized laboratory services may also place pressure on testing prices and lead to duplicated infrastructure investment. Future competitive advantage will increasingly depend on regulatory approvals, companion diagnostic partnerships, liquid biopsy performance, clinical interpretation capabilities, reimbursement access, and real-world evidence demonstrating clinical utility.
This report is a detailed and comprehensive analysis for global Comprehensive Genomic Profiling market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Comprehensive Genomic Profiling market size and forecasts, in consumption value ($ Million), 2021-2032
Global Comprehensive Genomic Profiling market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Comprehensive Genomic Profiling market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Comprehensive Genomic Profiling market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Comprehensive Genomic Profiling
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Comprehensive Genomic Profiling market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Guardant Health, Caris Life Sciences, Tempus AI, Labcorp, NeoGenomics, Exact Sciences, Personalis, Illumina, Thermo Fisher Scientific, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Comprehensive Genomic Profiling market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Tissue-based Profiling
Liquid Biopsy Profiling
Other
Market segment by Testing Scope
Medium Panels (50–199 Genes)
Large Panels (200–599 Genes)
Extended Panels (600–999 Genes)
Other
Market segment by Sequencing Approach
Targeted DNA Sequencing
Integrated DNA and RNA Sequencing
Whole-exome Sequencing
Whole-transcriptome Sequencing
Other
Market segment by Application
Hospitals and Cancer Centers
Independent Clinical Laboratories
Pharmaceutical and Biotechnology Companies
Other
Market segment by players, this report covers
Roche
Guardant Health
Caris Life Sciences
Tempus AI
Labcorp
NeoGenomics
Exact Sciences
Personalis
Illumina
Thermo Fisher Scientific
QIAGEN
Agilent Technologies
SOPHiA GENETICS
Sysmex
Burning Rock Biotech
Genetron Health
Geneseeq
BGI Genomics
Amoy Diagnostics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Comprehensive Genomic Profiling product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Comprehensive Genomic Profiling, with revenue, gross margin, and global market share of Comprehensive Genomic Profiling from 2021 to 2026.
Chapter 3, the Comprehensive Genomic Profiling competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Comprehensive Genomic Profiling market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Comprehensive Genomic Profiling.
Chapter 13, to describe Comprehensive Genomic Profiling research findings and conclusion.

Buy now